The share price of antimicrobial treatmentsdeveloper Destiny Pharma (LON: DEST) has done badly since the shares were recommended back in June. The key to the progress of the share price is likely to be positive news about the phase 3 trials for X-73, which prevents post-surgical infections, and c.diff prevention treatment NTCD-M3.
The phase 2b study results for XF-73 nasal gel were better than many expected and the prospects for both potential treatments are good. A phase 3 study design proposal has been submitted to the authorities and the details could be finalised before the end of the ...
